摘要
目的探讨那格列奈治疗2型糖尿病的有效性与安全性。方法将2013年3月~2015年3月我院收治的69例2型糖尿病患者分为两组,实验组35例给予那格列奈治疗,对照组34例给予瑞格列奈治疗。结果实验组糖化血红蛋白[（6.11±1.07）%]、空腹血糖[（6.10±1.12）mmol/L]、餐后2 h血糖[（8.09±2.21）mmol/L]少于对照组[糖化血红蛋白（8.22±3.31）%、空腹血糖（8.51±3.40）mmol/L、餐后2 h血糖（11.7168±5.23）mmol/L],其总有效率（94.29%）高于对照组（70.59%）,2组差异有统计学意义（P〈0.05）。结论那格列奈可有效治疗2型糖尿病,疗效高,安全性强。
Objective To investigate the treatment of type 2 diabetes, nateglinide efficacy and safety. Methods March 2013 to March 2015 in our hospital 69 cases of type 2 diabetes patients were divided into two groups, the experimental group of 35 patients received treatment nateglinide, repaglinide control group of 34 patients given treatment. Results Theexperimental group glycated hemoglobin [（6.11±1.07）%], fasting plasma glucose [（6.10±1.12） mmol/L], 2h postprandial glucose [（8.09±2.21） mmol/L] than the control group [glycated hemoglobin（8.22±3.31）%, fasting plasma glucose（8.51±3.40） mmol/L, 2h postprandial glucose（11.7168±5.23） mmol/L], its total efficiency（94.29%） was higher（70.59%）, group 2 the difference was statistically significant（P〈0.05）. Conclusion Nateglinide is effective in treating type 2 diabetes, high efficacy, safety and strong.
出处
《中国继续医学教育》
2015年第15期134-135,共2页
China Continuing Medical Education
